Next we examined the possible contribution of the endogenous ANXA1 and its receptor FPR2 on the BBB disruption in AD utilizing Aβ42‐treated bEnd.3 cells and the brain capillaries of 9‐ to 10‐month‐old 5XFAD mice. This evidence concerns the gene ANXA1 and Alzheimer disease.